ClinicalTrials.gg
Sign In

Drug

KRAS G12D Inhibitor HRS-4642 clinical trials

Also written HRS-4642.

studies test it
11
open now
9
in phase 3
0
first study started
2022

Keep track of what changes. Save the KRAS G12D Inhibitor HRS-4642 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Development codes

HRS-4642
5

Combined with it in one product

HRS-4642+NALIRIFOX
1
HRS-4642+NALIRIFOX+Adebrelimab
1
SHR-A2102+HRS-4642
1
HRS-4642;Adebrelimab Injection; nab-paclitaxel; gemcitabine
1
SHR-A2102, HRS4642 and Adebrelimab
1

Studies by the year they started

11 studies that test it; most in 2026 (4)

Studies that test KRAS G12D Inhibitor HRS-4642, by start year
YearStudies
20221
20243
20253
20264

By phase

A phase 1/2 study counts in both.

Phase 1
5
Phase 2
10

What it is tested for

Each study’s main condition, where its own words name it.

Pancreatic Neoplasms
3
Neoplasms
1
Biliary Tract Neoplasms
1

Who runs them

Industry 3 · Other 8

Jiangsu HengRui Medicine Co., Ltd. (2) · Fudan University (2) · Shanghai Zhongshan Hospital (2) · West China Hospital (1) · Changhai Hospital (1) · Henan Cancer Hospital (1) · The First Affiliated Hospital with Nanjing Medical University (1) · Shanghai Hengrui Pharmaceutical Co., Ltd. (1)

Often tested with

Tested in the same studies.

Adebrelimab (3) · Notiretatug rezetecan (2) · Nimotuzumab (1) · Fluorouracil/Liposomal Irinotecan/Leucovorin/Oxaliplatin Regimen (1) · SHR-1701 (1) · Anti-CTLA-4 Monoclonal Antibody SHR-8068 (1) · Xelox (1) · HRS-7058 (1)

Studies

Open first, then newest update. How each study uses KRAS G12D Inhibitor HRS-4642 is read from its arms, and is right about nine times in ten.

Testing it · 11

Given in every arm · 3 — KRAS G12D Inhibitor HRS-4642 is usual care beside what is tested